Avicanna Inc. (TSX:AVCN)

Market Cap	17.90M -45.7%
Revenue (ttm)	25.31M -0.2%
Net Income	-3.73M
EPS	-0.03
Shares Out	137.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Open	0.1300
Previous Close	0.1300
Day's Range	0.1300 - 0.1300
52-Week Range	0.0950 - 0.2975
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatol...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 112
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: AVCN

Financial Performance

In 2025, Avicanna's revenue was 25.48 million, an increase of 0.08% compared to the previous year's 25.46 million. Losses were -2.76 million, -39.75% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 28, 2026

Data Sources Report a data error